Mature B-cell Malignancies
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BeOne MedicinesCA - San Carlos
2 programs1
1
ZanubrutinibPhase 1/2Small Molecule1 trial
BGB-11417Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
BeOne MedicinesZanubrutinib
InnoCareICP-248
BeOne MedicinesBGB-11417
Clinical Trials (3)
Total enrollment: 78 patients across 3 trials
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
Start: Jan 2020Est. completion: Jun 2025
Phase 1/2Completed
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Start: Apr 2024Est. completion: Oct 202778 patients
Phase 1Recruiting
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Start: Jul 2021Est. completion: Apr 2026
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 78 patients
2 companies competing in this space